X-Chem, Inc. has expanded its collaboration with Janssen Biotech, Inc. to discover new drug leads for the treatment of inflammatory disease. The multi-target expansion builds on their existing discovery and license partnership entered into in December 2014, and facilitated by Johnson & Johnson Innovation. This agreement will apply X-Chem’s DEX platform to identify novel modulators for challenging disease targets, following the licensing of multiple series of X-Chem-discovered small molec...